References
- Khorana AA et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119:648–655.
- Kessler CM. The link between cancer and venous thromboembolism: a review. Am J Clin Oncol. 2009;32: S3–S7
- Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160:809–815.
- Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293:715–722.
- Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22:vi85–vi92
- ASCO 2015 Guidelines/VTE. Available at http://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/VTE-Summary-of-Recs.pdf
- With permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cancer-Associated Venous Thromboembolic Disease V.2.2018 - August 27, 2018. © National Comprehensive Cancer all rights reserved. Accessed 10.12.2018. To view the most recent and complete version of the guideline, go online to WWW.NCCN.org
- National Institute for Health and Care Excellence (2018) Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline (NG89). Available at https://www.nice.org.uk/guidance/ng89. Last accessed December 2018
- van Es N, CoppensM, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124(12):1968–1975
- Khorana AA. et al Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380:720–728
- Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012; 10:807–14.
- Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S et al. Apixaban for the prevention of thromboembolism in Immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019;94(6):635–640
- Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011; 9:653–63.
- Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–77.
- Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D et al. Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy, a 3-Month Interim Analysis. ASH 2018. https://ash.confex.com/ash/2018/webprogram/Paper112577.html (accessed January 14, 2019).
- Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 21; 380:711–719
- Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med.2018 15; 378:615–624.
- Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al. Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 10; 36:2017–2023.
- McBane II R, Loprinzi CL, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A. et al. Apixaban and Dalteparin in Active Malignancy Associated Venous Thromboembolism. The ADAM VTE Trial. J Thromb Haemost. 2019. [Epub ahead of print]
- Agnelli G. Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. N Engl J Med. 2019; 380(8):781–783
- Brunetti ND, Tricarico L, Correale M, De Gennaro L, Santoro F, Ieva R et al. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials. J Thromb Thrombolysis. 2019. [Epub ahead of print]